[1]
|
杨欢欢, 陈虹. 肺癌合并肺栓塞的研究进展[J]. 中华结核和呼吸杂志, 2020, 43(7): 577-581.
|
[2]
|
Panahi, L., Horseman, M., Weston, J., et al. (2021) Review of Medical Therapies for the Management of Pulmonary Embolism. Medicina, 57, 110. https://doi.org/10.3390/medicina57020110
|
[3]
|
Grilz, E., Posch, F., Nopp, S., et al. (2021) Relative Risk of Arterial and Venous Thromboembolism in Persons with Cancer vs. Persons without Cancer—A Nationwide Analysis. European Heart Journal, 42, 2299-2307.
https://doi.org/10.1093/eurheartj/ehab171
|
[4]
|
Becattini, C., Franco, L., Lee, A., et al. (2021) Treatment of Venous Thromboembolism in Cancer Patients: The Dark Side of the Moon. Cancer Treatment Reviews, 96, Article ID: 102190. https://doi.org/10.1016/j.ctrv.2021.102190
|
[5]
|
Moik, F., van Es, N., Posch, F., et al. (2020) Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study. Cancers, 12, 2493.
https://doi.org/10.3390/cancers12092493
|
[6]
|
Joanna, R.S.S., Kim, A.S., Thapa, B., et al. (2021) Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy. Med (N Y), 2, 423-434. https://doi.org/10.1016/j.medj.2021.02.002
|
[7]
|
Wang, W.W., Ning, S.W., et al. (2018) Lung Cancer and Pulmonary Embolism: What Is the Relationship? A Review. Journal of Cancer, 9, 3046-3057. https://doi.org/10.7150/jca.26008
|
[8]
|
Guo, J., et al. (2019) Comparison among Different Presentations of Venous Thromboembolism Because of Lung Cancer. The Clinical Respiratory Journal, 13, 574-582. https://doi.org/10.1111/crj.13060
|
[9]
|
Liu, B., Zheng, Y., et al. (2020) Analysis on Risk Factors of Lung Cancer Complicated with Pulmonary Embolism. The Clinical Respiratory Journal, 15, 65-73. https://doi.org/10.1111/crj.13270
|
[10]
|
Chaudhary, R., et al. (2020) Direct Oral Anticoagulants: A Review on the Current Role and Scope of Reversal Agents. Journal of Thrombosis and Thrombolysis, 49, 271-286. https://doi.org/10.1007/s11239-019-01954-2
|
[11]
|
Shnayder, N.A., Petrova, M.M., Shesternya, P.A., et al. (2021) Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions. Biomedicines, 9, 451.
https://doi.org/10.3390/biomedicines9050451
|
[12]
|
Iglesias, T.P.D. (2020) Venous Thromboembolism Treatment and Prevention in Cancer Patients: Can We Use Pills Yet? Current Treatment Options in Oncology, 21, 102-112. https://doi.org/10.1007/s11864-020-00744-w
|
[13]
|
Khorana, A.A., Liebman, H., Rosovsky, R., et al. (2021) Prediction and Prevention of Cancer-Associated Thromboembolism. The Oncologist, 26, e2-e7. https://doi.org/10.1002/onco.13569
|
[14]
|
Margaret, C.F., Alan, S.G., Priya, A.P., et al. (2021) Anticoagulant Treatment Satisfaction with Warfarin and Direct Oral Anticoagulants for Venous Thromboembolism. Journal of Thrombosis and Thrombolysis.
|
[15]
|
Goto, E., Ishimitsu, T. and Kato, T. (2020) Factor Xa Inhibitors in Clinical Practice: Comparison of Pharmacokinetic Profiles. Drug Metabolism and Pharmacokinetics, 35, 151-159. https://doi.org/10.1016/j.dmpk.2019.10.005
|
[16]
|
Dunois, C. (2021) Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). Biomedicines, 9, 445.
https://doi.org/10.3390/biomedicines9050445
|
[17]
|
Wu, T.T., Wu, L.S., Chen, W.J., et al. (2021) Risk of Intracranial Hemorrhage with Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Neurology, 1-9.
|
[18]
|
Spyropoulos, A.C., Ageno, W., Albers, G.W., et al. (2020) Post-Discharge Prophylaxis with Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. Journal of the American College of Cardiology, 75, 3140-3147. https://doi.org/10.1016/j.jacc.2020.04.071
|
[19]
|
Wysokinski, W.E., Casanegra, A.I., Vlazny, D.T., et al. (2019) Comparison of Apixaban to Rivaroxaban and Enoxaparin in Acute Cancer-Associated Venous Thromboembolism. American Journal of Hematology, 94, 1185-1192.
https://doi.org/10.1002/ajh.25604
|
[20]
|
王声祥, 任艳平, 李楠, 等. 阿哌沙班、利伐沙班、达比加群酯、依诺肝素预防髋膝关节置换术后静脉血栓形成的成本-效果分析[J]. 中国医院药学杂志, 2020, 40(2): 208-212.
|
[21]
|
Yagi, N., Nagai, K., Tanaka, T., et al. (2021) Current Status of Oral Anticoagulant Adherence in Japanese Patients with Atrial Fibrillation: A Claims Database Analysis. Journal of Cardiology. https://doi.org/10.1016/j.jjcc.2021.02.007
|
[22]
|
Kuderer, N.M., Culakova, E., Lyman, G.H., et al. (2018) Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). The Oncologist, 23, 247-255.
https://doi.org/10.1634/theoncologist.2017-0205
|
[23]
|
Chiari, R., Landi, L., Morelli, A.M., et al. (2020) ROS1-Rearranged Non-Small-Cell Lung Cancer Is Associated with a High Rate of Venous Thromboembolism: Analysis from a Phase II, Prospective, Multicenter, Two-Arms Trial (METROS). Clinical Lung Cancer, 21, 15-20. https://doi.org/10.1016/j.cllc.2019.06.012
|
[24]
|
O’Connell, C., Goldhaber, S.Z., et al. (2021) Treatment of Cancer-Associated Venous Thromboembolism with Low- Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. The Oncologist, 26, e8-e16. https://doi.org/10.1002/onco.13584
|
[25]
|
马旭, 韩森, 方健. 肿瘤相关静脉血栓栓塞症中新型口服抗凝药应用进展[J]. 中华肿瘤防治杂志, 2021, 28(3): 237-242.
|
[26]
|
Verso, M. and Di Nisio, M. (2020) Management of Venous Thromboembolism in Cancer Patients: Considerations about the Clinical Practice Guideline Update of the American Society of Clinical Oncology. European Journal of Internal Medicine, 71, 4-7. https://doi.org/10.1016/j.ejim.2019.10.033
|
[27]
|
马军, 秦叔逵, 吴一龙, 等. 肿瘤相关静脉血栓栓塞症预防与治疗指南(2019版) [J]. 中国肿瘤临床, 2019, 46(13): 653-660.
|
[28]
|
Muñoz Martín, A.J., Escobar, I.G., Montero, R.M., et al. (2020) SEOM Clinical Guideline of Venous Thromboembolism (VTE) and Cancer (2019). Clinical and Translational Oncology, 22, 171-186.
https://doi.org/10.1007/s12094-019-02263-z
|
[29]
|
成伟丽, 陈媛, 李金凤. 利伐沙班配合低分子肝素对肺癌患者血栓发生率及凝血功能的影响观察[J]. 中国实验诊断学, 2020, 24(10): 1623-1626.
|
[30]
|
Marshall, A., Hill, C., Hale, D., et al. (2020) Treatment of Cancer-Associated Venous Thromboembolism: 12-Month Outcomes of the Placebo versus Rivaroxaban Randomization of the SELECT-D Trial (SELECT-D: 12m). Journal of Thrombosis and Haemostasis, 18, 905-915. https://doi.org/10.1111/jth.14752
|
[31]
|
Mantha, S., Miao, Y.M., Sarasohn, D.M., et al. (2017) Safe and Effective Use of Rivaroxaban for Treatment of Cancer-Associated Venous Thromboembolic Disease: A Prospective Cohort Study. Journal of Thrombosis and Thrombolysis, 43, 166-171. https://doi.org/10.1007/s11239-016-1429-1
|
[32]
|
Howlett, J., Fagnoni, P. and Quantin, C. (2020) Are Direct Oral Anticoagulants an Economically Attractive Alternative to Low Molecular Weight Heparins in Lung Cancer Associated Venous Thromboembolism Management? Journal of Thrombosis and Thrombolysis, 50, 642-651. https://doi.org/10.1007/s11239-020-02047-1
|
[33]
|
Khorana, A.A., Carrier, M., Meyer, G., et al. (2020) Prevention of Venous Thromboembolism in Ambulatory Patients with Cancer. ESMO Open, 5, E000948. https://doi.org/10.1136/esmoopen-2020-000948
|
[34]
|
Riess, H., Weitz, J.I., et al. (2021) Treatment of Cancer-Associated Thrombosis: The Evolution of Anticoagulant Choice and Clinical Insights into Practical Management. Critical Reviews in Oncology/Hematology, 157, Article ID: 103125. https://doi.org/10.1016/j.critrevonc.2020.103125
|
[35]
|
Duffett, L., et al. (2020) Pulmonary Embolism: Update on Management and Controversies. The BMJ, 370, m2177.
https://doi.org/10.1136/bmj.m2177
|
[36]
|
Zhang, X., Wang, X.H., Liao, K., et al. (2021) Current Use of Rivaroxaban in Elderly Patients with Venous Thromboembolism (VTE). Journal of Thrombosis and Thrombolysis, 1-9. https://doi.org/10.1007/s11239-021-02415-5
|